Physician Resources
Recently Added |view more
Course
Optimizing Treatment Strategies for Localized and Advanced Genitourinary Malignancies
The management of advanced kidney, bladder, and prostate cancer is rapidly evolving, and new robotic and minimally invasive surgical techniques are now available. This CME program is designed to address the challenges physicians face in ...
Course
23rd Annual Highlights of the 2024 San Antonio Breast Cancer Symposium
Presented by Fox Chase Cancer Center and the Temple Health Office for Continuing Medical Education, this education program is designed to help medical, radiation, and surgical oncologists, gynecologists, and radiologists translate the ...
News
Researchers at Fox Chase Cancer Center and Lewis Katz School of Medicine at Temple University have identified factors that, if addressed, could decrease incidence of aggressive prostate cancer in areas where rates are highest — often Black ...
News
Tackling Anything Patients Need Before, During, and After Urologic Surgery
Growing up, Mary Ellen Day was athletic and focused—dreaming that one day, she would become a ‘real’ cheerleader.
News
Fox Chase Cancer Center Welcomes Dr. J. Ryan Mark
Fox Chase Cancer Center is pleased to announce the hiring of J. Ryan Mark, MD, FACS, as an Associate Professor in the Department of Urology at Fox Chase Cancer Center and a Fox Chase – Temple Urologic Institute provider.
News
ENDING THE RELIANCE ON BCG
A Phase III clinical trial for bladder cancer
The Phase III randomized trial compares Bacillus Calmette-Guerin (BCG) immunotherapy, the standard-of-care intravesical treatment for high grade non-muscle invasive bladder cancer, versus intravesical Docetaxel and Gemcitabine treatment in BCG naïve patients.
Document
DEPARTMENT OF HEMATOLOGY/ONCOLOGY THORACIC CANCERS CLINICAL TRIALS
For general questions about clinical trials, call 215-214-1515 or visit FoxChase.org/ClinicalTrials.
News
The study is a phase one, single-site, dose-escalation study for patients with myeloproliferative neoplasms unresponsive to any JAK2 inhibitor. It combines two oral medications, Pacritinib and Talazoparib, and is for transplant-ineligible patients.